BLA 761077 · Amgen INC
Aimovig
Erenumab-Aooe · Injection
NovelLast checked: Nov 20, 2026Latest source record: Jun 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 17, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
66
11 Phase 3, 9 recruiting
FAERS reports
55,567
12,192 serious, 3,183 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 14, 2026.
AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
Mechanism: Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 3, 2022 Supplement 15 · Efficacy LetterLabel
- Mar 11, 2019 Supplement 1 · Efficacy LetterLabel
- May 17, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- AIMOVIG · ERENUMAB-AOOE 70MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Erenumab" as an intervention, any sponsor and status, largest first.
AmgenAmgen (AMGN)
NCT04265755 · 1,406 participants · Start Oct 26, 2020 · Primary completion Jan 18, 2023
Drug: Erenumab · For: Migraine
Sites: Glostrup Municipality, Denmark; Reykjavik, Iceland
- Registry for Migraine - Clinical CoreStatus unknown
Danish Headache CenterAcademic, hospital or other
NCT04603976 · 1,000 participants (planned) · Start Sep 25, 2020 · Primary completion Oct 2022
Drug: Erenumab · For: Migraine
Sites: Glostrup Municipality, Denmark
- Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02456740 · 955 participants · Start Jul 17, 2015 · Primary completion Sep 5, 2016
Drug: Erenumab; Placebo · For: Migraine
Sites: Phoenix, Arizona; Anaheim, California; Encino, California · 129 sites in all
- Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03333109 · 900 participants · Start Feb 8, 2018 · Primary completion Jan 13, 2020
Drug: Erenumab · For: Episodic Migraine
Sites: CABA, Argentina; Buenos Aires, Argentina; Ciudad Autonoma de Bs As, Argentina · 81 sites in all
- Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic MigrainePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03828539 · 777 participants · Start Feb 22, 2019 · Primary completion Jul 29, 2020
Drug: Erenumab; Topiramate and 2 more · For: Migraine
Sites: Stuttgart, Germany; Marburg Wehrda, Germany; Hanover, Germany · 79 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04084314 · 701 participants · Start Sep 30, 2019 · Primary completion Feb 23, 2023
Drug: Erenumab · For: Migraine; Migraine Disorders; Migraine Headache
Sites: Stuttgart, Germany; Marburg Wehrda, Germany; Hanover, Germany · 75 sites in all
- A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine PreventionPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02066415 · 667 participants · Start Mar 5, 2014 · Primary completion Feb 24, 2016
Drug: Erenumab; Placebo · For: Treatment for Prevention of Chronic Migraine
Sites: La Jolla, California; Newport Beach, California; San Francisco, California · 74 sites in all
- Study of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03927144 · 621 participants · Start May 15, 2019 · Primary completion Oct 1, 2021
Drug: AMG334; Oral Prophylactic · For: Episodic Migraine
Sites: Stanford, California; New Haven, Connecticut; Stamford, Connecticut · 112 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device difficult to use10,278
- accidental exposure to product10,273
- wrong technique in product usage process9,519
- drug dose omission by device6,743
- migraine5,427
- drug ineffective4,511
- headache3,684
- constipation3,196
- product storage error2,980
- injection site pain2,934
- off label use2,925
- nausea2,559
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 10 |
| 2018 | 7,441 |
| 2019 | 11,258 |
| 2020 | 8,628 |
| 2021 | 6,012 |
| 2022 | 5,931 |
| 2023 | 5,750 |
| 2024 | 5,180 |
| 2025 | 3,093 |
| 2026 | 2,252 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ, Reuter U, Hallström Y, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R, Huessler EM, Puledda F, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
Sacco S, Amin FM, Ashina M, et al. · J Headache Pain 2022 · Systematic Review, Practice Guideline
- Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P, Dolezil D, Paemeleire K, et al. · JAMA Neurol 2024 · Research Support, Non-U.S. Gov't, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.